teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
Published 3 years ago • 1.1K plays • Length 9:57
Download video MP4
Download video MP3
Similar videos
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
-
11:22
updated efficacy/safety results of majestec-1 (teclistamab) at asco 2022
-
7:25
updated data: phase 1/2 majestec-1 study evaluating teclistamab, a bcma x cd3 bispecific antibody
-
2:21
180 updated phase 1 results of teclistamab, a bcma x cd3 bispecific antibody
-
8:12
evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
4:28
first-in-human study of tnb-383b, a bcma x cd3 bispecific t-cell redirecting antibody, in pts w/rrmm
-
7:26
regn5458, a bcmaxcd3 bispecific monoclonal antibody, in a phase 1/2 1st-in-human study in rrmm pts
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
3:41
teclistamab: bcma x cd3 bispecific antibody in rrmm
-
5:53
evaluation of teclistamab in rrmm patients following exposure to other bcma-targeted agents
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
6:36
updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory mm
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
4:56
updates on phase 1b trimm-2 study results of teclistamab daratumumab presented at eha 2022
-
5:06
durability of responses with biweekly dosing of teclistamab in pts with relapsed/refractory myeloma
Clip.africa.com - Privacy-policy